A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea
Cabergoline is a long-acting dopamine-agonist drug that suppresses prolactin secretion and restores gonadal function in women with hyperprolactinemic amenorrhea. We designed a study to compare its safety and efficacy with those of bromocriptine, which has been the standard therapy. A total of 459 wo...
Saved in:
Main Authors: | Ismail, I.S., Webster, J., Piscitelli, G., Polli, A., Ferrari, C.I., Scanlon, M.F. |
---|---|
Format: | Article |
Language: | English |
Published: |
Massachusetts Medical Society
1994
|
Subjects: | |
Online Access: | http://eprints.um.edu.my/10438/1/A_COMPARISON_OF_CABERGOLINE_AND_BROMOCRIPTINE_IN_THE_TREATMENT.pdf http://eprints.um.edu.my/10438/ |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The efficacy and tolerability of long-term cabergoline therapy in hyperprolactinaemic disorders an open, uncontrolled, multicentre study
by: Ismail, I.S., et al.
Published: (1993) -
Bromocriptine for type 2 diabetes mellitus
by: Ooi, Cheow Peng, et al.
Published: (2013) -
Endocrine and metabolic effects of growth hormone treatment
by: Ismail, I.S., et al.
Published: (1993) -
Cabergoline therapy versus repeated surgery in post-operative residual non-functioning pituitary adenomas (NFPA): a 10-year clinical outcome analysis
by: Nordin, Normala, et al.
Published: (2019) -
Cholinergic control of growth hormone (GH) responses to GH-releasing hormone in insulin dependent diabetics: evidence for attenuated hypothalamic somatostatinergic tone and decreased GH autofeedback
by: Ismail, I.S., et al.
Published: (1993)